isoxazoles has been researched along with Leukemia, Lymphocytic, Chronic, B-Cell in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alinari, L; Baiocchi, RA; Baskin, E; Beaver, L; Blachly, JS; Bollag, G; Brinton, L; Byrd, JC; Cannon, M; Carias, H; Dong, K; El-Gamal, D; Ewing, T; Goettl, VM; Grieselhuber, NR; Habets, G; Harrington, B; Hing, ZA; Ibrahim, P; Lai, TH; Lapalombella, R; Lehman, AM; Lucas, DM; Ma, Y; Marimuthu, A; Mathé, EA; Matusow, B; Mitchell, S; Nespi, M; Ozer, HG; Powell, B; Rezaei, H; Sampath, D; Sanftner, L; Severson, P; Shellooe, R; Shi, S; Spevak, W; Tantoy, C; Tsang, G; Walters, J; Williams, K; Woyach, JA; Yu, L; Zhang, C; Zhang, J; Zhang, Y | 1 |
| Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T | 1 |
| Gray, M; Leonard, N; McCrory, R; Smyth, J; Woodman, A | 1 |
| Burnett, AK; Fegan, C; Pearce, L; Pepper, C; Walsby, E | 1 |
| Best, OG; Mulligan, SP | 1 |
| Bernstein, SH; Chiorazzi, N; Felgar, RE; Kaur, K; Phipps, RP; Pollock, SJ; Ryan, EP | 1 |
| Bushnell, TP; Friedman, AE; Phipps, RP; Rahman, I; Ryan, EP | 1 |
| Bogner, C; Decker, T; Oelsner, M; Peschel, C; Ringshausen, I | 1 |
8 other study(ies) available for isoxazoles and Leukemia, Lymphocytic, Chronic, B-Cell
| Article | Year |
|---|---|
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Nuclear Proteins; Pyridines; Pyrroles; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays | 2018 |
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine | 2012 |
Native kidney BK virus nephropathy associated with chronic lymphocytic leukaemia.
Topics: Aged; BK Virus; DNA, Viral; Humans; Immunosuppressive Agents; Isoxazoles; Kidney Diseases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Polymerase Chain Reaction; Polyomavirus Infections; Prognosis; Tumor Virus Infections | 2012 |
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cells, Cultured; Cytoprotection; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Resorcinols; Signal Transduction; Survivin; Tumor Microenvironment; Vidarabine | 2012 |
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
Topics: Animals; Apoptosis; CD40 Antigens; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunophenotyping; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phenotype; Receptor Tyrosine Kinase-like Orphan Receptors; Resorcinols; STAT3 Transcription Factor; Stromal Cells; Vidarabine | 2012 |
Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells.
Topics: B-Lymphocytes; Cell Growth Processes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprost; Dinoprostone; Enzyme Activation; Humans; Immunoglobulin Heavy Chains; Immunohistochemistry; Indomethacin; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrobenzenes; Pyrazoles; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.
Topics: Animals; B-Lymphocytes; Catalytic Domain; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Glutamate-Cysteine Ligase; Glutathione; Humans; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Mice; Mice, Knockout; Oxidative Stress; Pyrazoles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Sulfones | 2008 |
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells.
Topics: Apoptosis; B-Lymphocytes; Crotonates; Cyclin A; Cyclin D3; Cyclin-Dependent Kinase 2; Cyclins; Dihydroorotate Dehydrogenase; DNA Replication; Drug Screening Assays, Antitumor; G1 Phase; Humans; Hydroxybutyrates; Immunologic Factors; Isoxazoles; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Prodrugs; Protein Processing, Post-Translational; Receptors, Immunologic; Receptors, Prostaglandin; Retinoblastoma Protein; Toluidines; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2008 |